Skip to main content

Table 1 Association of patient/tumor characteristics with CHEK2 H371Y mutation status

From: Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer

Characteristics n Carriers, n (%) Non-carriers, n (%) P-value
Total 2334 39 (1.7) 2295 (98.3)  
Age     0.036
  ≤50y 1415 30 (76.9) 1385 (60.3)  
  >50y 919 9 (23.1) 910 (39.7)  
ER     0.30
  Positive 1365 26 (66.7) 1339 (58.3)  
  Negative 969 13 (33.3) 956 (41.7)  
PgR     0.26
  Positive 1108 22 (56.4) 1086 (47.3)  
  Negative 1226 17 (43.6) 1209 (52.7)  
HER2     0.038
  Positive 714 6 (15.4) 708 (30.8)  
  Negative 1620 33 (84.6) 1587 (69.2)  
TNBC     0.61
  Non-TNBC 1837 32 (82.1) 1805 (78.6)  
  TNBC 497 7 (17.9) 490 (21.4)  
Tumor size     0.70
  <2 cm 786 12 (30.8) 774(33.7)  
  ≥2 cm 1548 27 (69.2) 1521(66.3)  
Lymph node     1.00
  Positive 1014 17 (43.6) 997 (43.6)  
  Negative 1314 22 (56.4) 1292 (56.4)  
  Unknown 6   6  
Nuclear grade     
  1 199 6(17.6) 193 (9.7) 0.29
  2 1518 24(70.6) 1494 (75.3)  
  3 302 4(11.8) 298 (15.0)  
  Unknown 315 5 310  
Histology     0.45
  Ductal 2064 33 (84.6) 2031 (88.5)  
  Others 270 6 (15.4) 264 (11.5)  
Chemotherapy type     0.27
  A-based,without a T 859 18 (46.2) 841 (36.6)  
  A-T containing 882 10 (25.6) 872 (38.0)  
  T-based,without a A 593 11(28.2) 582(25.4)  
Trastuzumab use     0.42
  Yes 108 3 (7.7) 105(4.6)  
  No 2226 36 (92.3) 2190(95.4)  
Surgery type     
  BCS 983 22 (56.4) 961 (41.9) 0.07
  Mastectomy 1351 17 (43.6) 1334 (58.1)  
  1. ER, Estrogen receptor; PgR, Progesterone receptor; HER2, Human epidermal growth factor receptor-2; A, Anthracycline; T, Taxane; BCS, Breast-conserving surgery.